For its third fiscal quarter (ending September 30), Ligand Pharmaceuticals Inc (NASDAQ: LGND) has reported a -34% decline in E.P.S. from $-0.59 a year ago to $-0.39 in the current quarter. E.P.S. were $2.54 for the latest four quarters through September 30 versus $1.21 for the same period a year ago — an increase of 110%.
Recent Price Action
Ligand Pharmaceuticals Inc (NASDAQ: LGND) stock closed at $129.90 on 11/7/24 after a major increase of 11.1%. Moreover, trading volume in this advance was exceptionally high at 270% of normal. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 18.3% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, LGND is expected to continue to be an important Value Builder.
Ligand Pharmaceuticals has a current Value Trend Rating of C (High Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Ligand Pharmaceuticals has a slightly negative Appreciation Score of 31 but a very high Power Rating of 90, with the High Neutral Value Trend Rating the result.
Rating Review
In light of this new information and very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment